Next-generation NovaSure® device for endometrial ablation: assessing ease-of-use among physicians by Pollock, Whitney & Jamieson, William
© 2012 Pollock and Jamieson, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Women’s Health 2012:4 109–113
International Journal of Women’s Health
Next-generation NovaSure® device for 
endometrial ablation: assessing ease-of-use  
among physicians
Whitney Pollock1
William Jamieson2
1The Gynecology Center, Pottsville, 
PA, USA; 2University of Cincinnati, 
Christ Hospital, Cincinnati, OH, USA
Correspondence: Whitney Pollock 
The Gynecology Center, 1816 West 
Market Street, Pottsville, PA 17901, USA 
Tel +1 570 628 9448 
Fax +1 570 628 9445 
Email whitneydo@yahoo.com
Objective: To compare physician assessment of the next-generation NovaSure® device to the 
original NovaSure device.
Design: Prospective open-label, unblinded survey utilizing Likert scales.
Setting: Community-based obstetrician and gynecology practices.
Patients: There were 270 evaluations completed by 168 physicians for women undergoing endo-
metrial ablation with the next-generation NovaSure device compared to the previous model.
Interventions: Physician survey across multiple community-based obstetrician and gynecol-
ogy practices.
Measurements and main results: In general, 53.7% of women had a normal uterus, with an 
average cavity length of 5.3 cm ± 0.9 cm, and 44.7% of women had a normal cervix. Overall, 
98.7% of physicians agreed or strongly agreed that they were satisfied with the performance of 
the next-generation NovaSure device compared with the previous device. Additionally, 89% of 
physicians rated the next-generation NovaSure device as superior to the previous device. The 
best rated features were the SureFit™ Cervical Seal, Smooth Access™ Tips, and the thumb-
pusher. No adverse events were reported in this study.
Conclusion: Community-based physicians rated the next-generation NovaSure device as 
superior to the previous model in a general population of women.
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Introduction
For women, normal menstrual bleeding patterns occur at an interval of 21 to 
35 days, with bleeding lasting 1 to 7 days.1 This equates to less than one tampon or 
pad, or ,80 mL of blood, for every 3-hour period.1 Menorrhagia is defined as excessive 
but regular cyclic bleeding of more than 7 days, passage of clots, or iron deficiency 
anemia.1 Prolonged bleeding over 12 days should be considered abnormal regardless 
of cyclic pattern.1 Pain and heaviness are the most frequently reported bothersome 
aspects of excessive or very excessive periods.2 In Western countries, up to 35% of 
women report excessive or very excessive bleeding.3,4 However, only 5% of women 
seek medical help for menorrhagia annually.4 Among women with excessive menstrual 
bleeding, 53% reported that their periods interfered with their life, compared with 
23% of community controls.5
Pharmacotherapy treatment options for excessive bleeding include oral contracep-
tives, danazol, progestens, etc.6 Surgical treatment options for excessive bleeding include 
endometrial ablation and hysterectomy. Hysteroscopic endometrial ablation offers an 
effective, less invasive alternative to hysterectomy. Physicians and patients should work 
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together to decide the best treatment option for an individual 
patient. For patients who wish to avoid major surgery and 
in whom childbearing is complete, endometrial ablation 
is a reasonable and effective alternative to   hysterectomy.7 
The NovaSure®  (Hologic,  Inc,  Marlborough,  MA)   
endometrial ablation procedure is intended to ablate the 
endometrial lining of the uterus in premenopausal women 
with excessive bleeding due to benign causes for whom 
childbearing is complete.8 To date, more than one million 
women have undergone the NovaSure procedure. Although 
widely accepted by physicians for use in endometrial ablation 
procedures, an initiative was undertaken to understand which 
features could be revised or enhanced to further improve 
the surgeons experience with the device. The manufacturer 
made several enhancements to the original device and 
a next-generation NovaSure device was released for com-
mercial use in 2010. Here we present community-based, 
physician-reported data evaluating the ease-of-use of the 
newly designed next-generation NovaSure device compared 
with the prior model.
Methods
The data presented here represent the findings of community-
based, physician-reported assessments on the ease-of-use 
of the next-generation NovaSure device. The objective was 
to compare physician assessment of the original NovaSure 
device to the next-generation NovaSure device. Physicians 
were asked to participate in the study based upon their use 
and experience with the NovaSure device and respondents 
were not compensated for their participation in this study. 
Participating physicians represented a diverse group that was 
representative of general, community-based practices. Their 
procedure volumes ranged from very low (a few per month) 
to multiple procedures per week. The study was a prospec-
tive open-label, unblinded survey utilizing Likert scales to 
determine whether the updated next-generation NovaSure 
device design was perceived better than the previous model 
in ease-of-use or component features. A 5-point Likert 
scale was used to assess ease-of-use items. Physicians rated 
the performance of the next-generation NovaSure device 
(1 = strongly disagree to 5 = strongly agree) and also com-
pared it with the previous model of the device (1 = inferior, 
2 = equal, and 3 = superior). Anatomic variability (cervix, 
uterine position, and cavity length) and procedural informa-
tion was also collected.
Subjects with benign endometrial pathology, uterine 
sound ,10 cm, intracavitary fibroids ,2 cm, and complete 
childbearing were evaluated. Ease-of-use during endometrial 
ablation using the new, revised design of the next-generation 
NovaSure device was compared with the previous NovaSure 
device.
Internal reliability of the survey was assessed via 
Cronbach’s alpha. Cronbach’s alpha is defined as: 
ασ σ =− −∑= KK i
k
YX // 11 1
22 ()
i  where K is the number of 
components σ X
2  is the variance of the observed total test 
scores, and σYi
2 is the variance of component i for the current 
sample of persons. Cronbach’s alpha is a measure of internal 
consistency, that is, how closely related a set of items are as 
Table 1 Assessment of uterus type
Uterus type Frequency (n) 
n = 257
Valid percent
Normal 138 53.7
Anteverted 56 21.8
retroverted 36 14.0
Verted 8 3.1
Anteflexed 6 2.3
Retroflexed 7 2.7
Flexed 5 1.9
Midline 1 0.4
Total 257 100.0
Table 2 Assessment of cavity length
Cavity length (cm) Frequency (n) 
n = 263
Valid percent
3.0 1 0.4
4.0 37 14.1
4.5 38 14.4
5.0 63 24.0
5.5 44 16.7
6.0 45 17.1
6.5 29 11.0
7.0 2 0.8
8.0 1 0.4
8.5 1 0.4
9.0 2 0.8
Total 263 100.0
Table 3 Assessment of cervix type
Cervix type Frequency (n)  
n = 257
Valid percent
Stenotic 19 7.4
Typical nulip 13 5.1
Normal 115 44.7
Typical multip 88 34.2
Patulous 22 8.6
Total 257 100.0
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a group. Higher alpha scores (.0.80) are more desirable and 
indicate better reliability.
Results
Ease-of-use assessed by a community-
based survey
Physicians (n = 168) from community-based obstetrics and 
gynecology practices rated six specific components of the 
next-generation NovaSure device. In total, 270 evaluations 
were completed, with 245 fully completed; 56 physicians 
completed two evaluations, and 26 physicians completed 
three or more evaluations. Patients included women 
  undergoing endometrial ablation with the next-generation 
NovaSure device. In general, 53.7% of women had a normal 
uterus and 21.8% had an anteverted uterus (Table 1). The 
average cavity length of women was 5.3 cm ± 0.9 cm with 
55.1% of women having a cavity length between 4.5 cm and 
5.5 cm (Table 2). Approximately 45% of women had a normal 
cervix and 34.2% had a typical multip cervix (Table 3).
Overall, 98.7% (155 of 157) of physicians agreed or 
strongly agreed that they were satisfied with the perfor-
mance of the next-generation NovaSure device compared 
with the previous device. Additionally, 89% (135 of 151) 
of physicians rated the next-generation NovaSure device as 
superior to the previous device (Figure 1). Physicians also 
assessed the overall device and specific components of the 
next-generation NovaSure device compared with the previ-
ous model (Figure 2A and B). Overall satisfaction of the 
next-generation NovaSure device was evaluated in patients 
with cavity lengths ranging from 4–9 cm. Additionally, 100% 
(149 of 149) of physicians agreed that the thumb-pusher on 
the next-generation NovaSure device was superior in patients 
with cavity lengths of . 7 cm. The next-generation NovaSure 
device was perceived as easier to insert in uterine cavities 
.7 cm (P = 0.16). More than 99% of physicians said that 
overall, the next-generation NovaSure device was similar 
or superior to the previous model in patients with a normal 
cervix. All physicians (100%) agreed that the next-generation 
NovaSure device was similar or superior to the previous 
model in patients with stenotic, typical nulip, typical multip, 
and patulous cervixes.
Physicians prefer the next-generation NovaSure device 
over the earlier design, regardless of patient anatomy. 
A few features were considered advantageous, including the 
redesigned cervical collar to provide a more complete seal 
and improve the ability to pass cavity integrity assessment, 
Smooth Access™ Tips to enhance array deployment, and a 
thumb-pusher to overcome a long vaginal canal (Table 4). 
Results of this survey are considered valid, as the Cronbach’s 
alpha was $0.80, indicating good reliability. This survey 
showed a high validity and reliability based on Cronbach’s 
alpha calculation for ease-of-use (Cronbach’s alpha = 0.841) 
and comparison items (Cronbach’s alpha = 0.823).
Discussion
Excessive menstrual bleeding can have a direct impact on 
a woman’s quality of life. Performing endometrial ablation 
is a viable treatment alternative to hysterectomy, and the 
goal of treatment is to improve the patient’s quality of life.9 
The NovaSure endometrial ablation system is intended to 
ablate the endometrial lining of the uterus in premeno-
pausal women with menorrhagia (excessive bleeding) due 
to benign causes for whom childbearing is complete. The 
current data demonstrate that recent enhancements made 
to the NovaSure device have been well-received by physi-
cians. The next-generation NovaSure device was designed 
based on surgeon feedback with the goal to enhance fea-
tures that would further improve the surgeons experience 
with the device. Several enhancements were made to the 
original device, and a next-generation NovaSure device 
was released for commercial use in 2010.
In the community-based survey, 98% of physicians were 
satisfied with the performance of the next-generation Nova-
Sure device, and 89% considered it as superior to the previous 
model. It is important to note that the data based on anatomic 
variability support the use of the next-generation NovaSure 
device in many patient types, which is relevant for general 
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Figure 1 Community-based physician survey: Preference.
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practitioner use. In this survey, more than 50% of women had 
a normal uterus and almost 22% had an anteverted uterus. 
The average cavity length in the women was 5.3 cm and 
55.1% of women had a cavity length of 4.5 cm, 5.0 cm, or 
5.5 cm. Cervix type also indicated that these women were 
representative of a general population as 44.7% had a normal 
cervix and 34.2% had a typical multip cervix. Regardless of 
anatomy, physicians preferred the next-generation device, and 
did not identify an anatomic configuration for which the prior 
device would have been preferred. Physicians considered 
the thumb-pusher, the SureFit™ Cervical Seal, and Smooth 
Access Tips as the best features of the   next-generation device. 
The thumb-pusher allows more leverage and control over 
the cervical collar. The next-generation NovaSure device 
SureFit Cervical Seal is larger, designed from softer material, 
provides a 70% greater coverage area, and may improve the 
procedure efficiency and patient comfort. Finally, the Smooth 
Access Tips allow for easier insertion of the device.
The results presented here are encouraging and support 
the changes and enhancements made in the next-genera-
tion NovaSure device. These data were collected among 
  community-based physicians and appear to be representative 
of a general population of women based upon their type of 
uterus and cervix and cavity length. Advantages with the next-
generation NovaSure device include a procedure that can be 
Figure 2 Community-based physician survey comparing the Next-Generation NovaSure device with the previous model. (A) Overall satisfaction. (B) Ease-of-use.
Notes: Survey was completed giving physicians four options for rating (inferior, equal, slightly better, or superior).
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performed in-office, and is quicker than many other hystero-
scopic procedures and less invasive than a hysterectomy.
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Table 4 Community-based physician survey: physician-rated best 
features
Feature Frequency (n) 
n = 245
Valid percent
Cervical seal 79 32.2
Smooth Access Tips 70 28.6
Thumb-pusher 66 26.9
Cervical collar 11 4.5
Ease-of-use 6 2.4
All 4 1.6
Seating 3 1.2
Deployment 2 0.8
Easier to sheath 2 0.8
Distal sheath 1 0.4
Ease-of-use 1 0.4
Total 245 100
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